Olutasidenib Maintenance
Pilot Trial of Olutasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients Carrying IDH1 Mutation With AML, MDS, or CMML Disease
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 15 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, Maintenance, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1976
- NCT Identifier
- NCT06543381
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.